The downregulation of miR-17 may represent an explanation for the effectiveness of these drugs in specific hematologic malignancies that are dependent on Myc pathway deregulation for their pathogenesis (e.g. chronic lymphocytic leukemia and aggressive lymphomas), since miR-17 functions synergistically with Myc to promote aggressive tumor growth in lymphoma[14]. The gene discussed is MYC; the disease is B-cell chronic lymphocytic leukemia.